MDxHealth SA Stock

Equities

MDXH

BE0974461940

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
2.47 USD 0.00% Intraday chart for MDxHealth SA +10.76% -37.31%
Sales 2023 64.39M 68.84M Sales 2024 * 73.53M 78.62M Capitalization 63.14M 67.51M
Net income 2023 -39M -41.7M Net income 2024 * -26M -27.8M EV / Sales 2023 1.51 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 0.86 x
P/E ratio 2023
-2.37 x
P/E ratio 2024 *
-2.46 x
Employees 255
Yield 2023 *
-
Yield 2024 *
-
Free-Float 97.37%
More Fundamentals * Assessed data
Dynamic Chart
1 week+10.76%
Current month-4.63%
1 month-0.80%
3 months-36.34%
6 months-1.20%
Current year-37.31%
More quotes
1 week
2.26
Extreme 2.26
2.61
1 month
2.21
Extreme 2.21
3.20
Current year
2.21
Extreme 2.21
4.64
1 year
2.21
Extreme 2.21
4.64
3 years
0.00
Extreme 0
17.80
5 years
0.00
Extreme 0
17.80
10 years
0.00
Extreme 0
62.00
More quotes
Date Price Change Volume
24-04-26 2.47 0.00% 26,967
24-04-25 2.47 -0.80% 40,509
24-04-24 2.49 +1.63% 37,177
24-04-23 2.45 +4.26% 33,713
24-04-22 2.35 +5.38% 45,573

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT

More quotes
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.47 USD
Average target price
6.333 USD
Spread / Average Target
+156.41%
Consensus